A partial agonist of PPARγ (EC50 = 1.351 μM in a transactivation assay); decreases non-fasting plasma glucose levels in diabetic db/db mice (ED90 = 3 mg/kg per day); decreases plasma levels of insulin and glucose in an oral glucose tolerance test in diet-induced obese rats at 5 and 10 mg/kg per day; in doxorubicin-resistant K562 human myelogenous leukemia cells

Balaglitazone – 5 mg

Brand:
Cayman
CAS:
199113-98-9
Storage:
-20
UN-No:
Non-Hazardous - /

Balaglitazone is a partial agonist of peroxisome proliferator-activated receptor γ (PPARγ; EC50 = 1.351 μM in a transactivation assay).{48619} It decreases non-fasting plasma glucose levels in diabetic db/db mice (ED90 = 3 mg/kg per day). Balaglitazone (5 and 10 mg/kg per day) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in diet-induced obese rats.{48620} In doxorubicin-resistant K562 human myelogenous leukemia cells, balaglitazone (25 μM) decreases P-glycoprotein (P-gp) levels, increases intracellular accumulation of the P-gp substrate rhodamine 123 (Item No. 16672), and sensitizes cells to doxorubicin (Item No. 15007).{48621}  

 

Available on backorder

Add to quotes
SKU: 28866 - 5 mg Category:

Description

A partial agonist of PPARγ (EC50 = 1.351 μM in a transactivation assay); decreases non-fasting plasma glucose levels in diabetic db/db mice (ED90 = 3 mg/kg per day); decreases plasma levels of insulin and glucose in an oral glucose tolerance test in diet-induced obese rats at 5 and 10 mg/kg per day; in doxorubicin-resistant K562 human myelogenous leukemia cells, it decreases P-gp levels, increases intracellular accumulation of rhodamine 123, and sensitizes cells to doxorubicin at 25 μM

Formal name: 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-2,4-thiazolidinedione

Synonyms:  DRF 2593

Molecular weight: 395.4

CAS: 199113-98-9

Purity: ≥98%

Formulation: A crystalline solid

Related products

  • A powerful effector in both the TetR and revTetR transcriptional regulator systems

    Anhydrotetracycline (hydrochloride) – 250 mg

    The tetracycline repressor (TetR) is a transcriptional regulator which normally binds tightly to its palindromic tetO operator DNA, blocking gene expression.{17508} Tet causes the repressor to dissociate from the DNA, allowing transcription to occur. A novel reverse TetR (revTetR) requires tetracycline as a co-repressor to bind tetO and block transcription.{17509,17510} Anhydrotetracycline (hydrochloride) is a powerful effector in both the tetracycline repressor (TetR) and reverse TetR (revTetR) systems, binding the Tet repressor 35-fold more strongly than Tet.{17508,17511} Moreover, anhydrotetracycline poorly binds the 30S ribosomal subunit, compared to Tet,{17512} so it does not act as a general inhibitor of translation and is a poor antibiotic. Perhaps related to this, the concentration of anhydrotetracycline that inhibits eukaryotic cell growth is more than a 1,000-fold above the dose that alters transcription through TetR.{17508}  

     

    Brand:
    Cayman
    SKU:10009542 - 250 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page
  • A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H

    (R)-Roscovitine – 1 mg

    Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}  

     

    Brand:
    Cayman
    SKU:10009569 - 1 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page
  • A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H

    (R)-Roscovitine – 5 mg

    Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}  

     

    Brand:
    Cayman
    SKU:10009569 - 5 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page
  • A zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers

    1,2-Dipalmitoyl-sn-glycero-3-PC – 25 mg

    1,2-Dipalmitoyl-sn-glycero-3-PC (DPPC) is a zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers, bilayers, and liposomes for use in a variety of applications.{14480,24261,14478,14479} It has been used in the formation of proteoliposomes for implantation of γ-glutamyl transpeptidase into human erythrocyte membranes.{14478} Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice.{14479}  

     

    Brand:
    Cayman
    SKU:10009473 - 25 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page